New study aims to predict which surgery patients are at highest risk in poorer nations
NCT ID NCT07621198
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study is building a risk prediction model for major complications and death within 30 days after major surgery, specifically for low- and middle-income countries. Researchers are collecting data on patient health, hospital resources, and safety practices from multiple international centers. The goal is to create a tool that helps doctors identify high-risk patients and improve surgical safety in resource-limited settings.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple tool that helps doctors in low-resource settings identify high-risk patients before surgery, potentially reducing preventable deaths.
- What could go wrong
- This is an observational study, not a treatment trial. The prediction model may not be accurate enough to change outcomes, and results may not apply to all settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR SURGERY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Departamental de Villavicencio
Villavicencio, Meta Department, 50001, Colombia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 4-Week Pre-Surgery boost cut complications in GI cancer surgery?
- Chin sensor may spot hidden danger during surgery
- Blood tests could predict infections in ICU patients
- Can a simple checklist save lives in the operating room?
- Can a simple heart rate drug prevent Surgery-Related heart attacks?
- New Painkiller's breathing risks scrutinized in 204-Patient trial